| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/22/2004 | US20040076967 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 04/22/2004 | US20040076956 Oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with DNA repair which are directed against the sequence; ascertaining genetic and/ or epigenetic parameters of DNA repair genes |
| 04/22/2004 | US20040076635 Genetic vaccine, polypeptide encoded by a nucleotide sequence genome, a vector, a transgenic cell, for preventing and treating viral infections |
| 04/22/2004 | US20040076633 Genetic vaccines comprising a 1H-imidazo(4,5-c)- 4-amine derivative as an adjuvant, for increasing immune responses in a mammal to the encoded antigen |
| 04/22/2004 | US20040076632 DNA vaccine against feline immunodeficiency virus |
| 04/22/2004 | US20040076622 Local production and/or delivery of anti-cancer agents by stromal cell precursors |
| 04/22/2004 | US20040076617 Culturing the progenitor cells with stromal cells in vitro, a medium comprising at least one interleukin-6 (IL-6) family cytokine; using for gene targeting, and therapeutic purposes |
| 04/22/2004 | US20040076613 Vector system |
| 04/22/2004 | US20040076610 Method of treating portal hypertension |
| 04/22/2004 | US20040076607 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 04/22/2004 | US20040076585 Nanoparticles of cyclic tetrapyrrolic compounds as gene and drug delivery carriers |
| 04/22/2004 | CA2823937A1 Hiv vaccine formulations |
| 04/22/2004 | CA2501940A1 Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use |
| 04/22/2004 | CA2501851A1 Circular dna molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| 04/22/2004 | CA2501752A1 Compositions, organisms and methodologies employing a novel human kinase |
| 04/22/2004 | CA2501633A1 Recombinant adenoviral vectors and applications thereof |
| 04/22/2004 | CA2501476A1 Hiv vaccine formulations |
| 04/22/2004 | CA2501289A1 Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof |
| 04/22/2004 | CA2498918A1 Stabilized naked dna compositions |
| 04/22/2004 | CA2497798A1 Production of peptides in plants as viral coat protein fusions |
| 04/22/2004 | CA2465860A1 Methods and compositions for therapeutic use of rna interference |
| 04/21/2004 | EP1411128A1 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars |
| 04/21/2004 | EP1411124A2 Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same |
| 04/21/2004 | EP1411063A1 Peptide nucleic acids |
| 04/21/2004 | EP1410035A2 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 04/21/2004 | EP1409748A2 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
| 04/21/2004 | EP1409740A2 Asthma-associated gene |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409734A2 Diagnosis and treatment of cancer |
| 04/21/2004 | EP1409710A1 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 04/21/2004 | EP1409701A2 Fluorescently labelled locked nucleic acids |
| 04/21/2004 | EP1409700A2 System for producing clonal or complex populations of recombinant adenoviruses, and the application of the same |
| 04/21/2004 | EP1409699A1 Recombinant vectors derived from adeno-associated virus expressing tam67 for gene therapy |
| 04/21/2004 | EP1409694A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 04/21/2004 | EP1409690A2 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 04/21/2004 | EP1409683A2 i HELICOBACTER /i PROTEINS, NUCLEIC ACIDS AND USES THEREOF |
| 04/21/2004 | EP1409680A2 Novel human proton-gated channels |
| 04/21/2004 | EP1409676A2 Cd109 nucleic acid molecules polypeptides and methods of use |
| 04/21/2004 | EP1409675A1 Gene involved in apoptosis regulation |
| 04/21/2004 | EP1409673A2 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 04/21/2004 | EP1409672A2 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 04/21/2004 | EP1409670A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression |
| 04/21/2004 | EP1409653A1 Viral mutants that selectively replicate in targeted human cancer cells |
| 04/21/2004 | EP1409650A1 Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof |
| 04/21/2004 | EP1409639A1 Epidermal growth factor receptorantisense oligonucleotides |
| 04/21/2004 | EP1409542A2 Blood group antigen fusion polypeptides and methods of use thereof |
| 04/21/2004 | EP1409534A2 Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof |
| 04/21/2004 | EP1409526A2 An inducer of apoptosis |
| 04/21/2004 | EP1409523A2 Pancam nucleic acids and polypeptides |
| 04/21/2004 | EP1409510A2 Biological pacemaker |
| 04/21/2004 | EP1409509A2 Antisense modulation of c-reactive protein expression |
| 04/21/2004 | EP1409506A1 Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| 04/21/2004 | EP1409025A1 Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies |
| 04/21/2004 | EP1409014A1 Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus |
| 04/21/2004 | EP1409012A1 Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| 04/21/2004 | EP1409008A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
| 04/21/2004 | EP1408909A2 Improved conditionally replicating vectors for inhibiting viral infections |
| 04/21/2004 | EP1408808A2 Methods for diagnosing and treating heart disease |
| 04/21/2004 | EP1287355B1 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 04/21/2004 | EP1212331B1 28-epirapalogs |
| 04/21/2004 | EP1053301B1 A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use |
| 04/21/2004 | EP0859847B1 Composition and method of imparting resistivity to hiv superinfection to cells |
| 04/21/2004 | EP0836647B1 Antiviral proteins, dna coding sequences therefor, and uses thereof |
| 04/21/2004 | EP0815218B1 Human vegf-specific antisense oligonucleotides |
| 04/21/2004 | CN1491283A Vector for introducing molecules in eukaryotic cells and molecules vectorized by same |
| 04/21/2004 | CN1491117A Compositions containing inclusion complexes |
| 04/21/2004 | CN1491116A Hepatitis B virus treatment |
| 04/21/2004 | CN1490323A Genome sequence of O-foot and mouth disease virus NYOO lines |
| 04/21/2004 | CN1490056A Immune method and composition for HIV-1 |
| 04/21/2004 | CN1146664C Fusion polypeptides comprising and IgE-binding domain and HSA component, and their diagnostic and therapeutic uses |
| 04/21/2004 | CN1146657C Construction and use of recombinant herpes simplex virus |
| 04/20/2004 | US6723708 Lithium chloride |
| 04/20/2004 | US6723707 Flanked by sv40 intron and polyadenylation signal sequences; genetic engineering |
| 04/20/2004 | US6723695 Cytotoxic epstein-barr virus (ebv) t-cell epitopes derived from ebv structural antigens; vaccines |
| 04/20/2004 | US6723561 Polypeptides |
| 04/20/2004 | US6723557 Provides a tool to identify the genes and factors involved in the polycystic kidney disease pathway, for drug screening and treatment; location of vulva (lov-1) gene |
| 04/20/2004 | US6723552 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| 04/20/2004 | US6723538 Therapy for infections, immunology diseases |
| 04/20/2004 | US6723534 Polypeptide for use in the treatment of fertility defects in humans |
| 04/20/2004 | US6723532 Plasmid for use in gene therapy |
| 04/20/2004 | US6723519 Compositions and method for determining the presence of rat PTTG peptide in a sample |
| 04/20/2004 | US6723511 Suppression of apoptosis in cell; obtain cells, incubate with blocking agent, monitor apoptosis in cells |
| 04/20/2004 | US6723322 Angiogenic Onchocerca volvulus proteins and uses thereof |
| 04/20/2004 | US6723315 Method for treating amyotrophic lateral sclerosis |
| 04/20/2004 | CA2044593C Method of in vivo delivery of functioning foreign genes |
| 04/16/2004 | CA2408207A1 Peptides binding protein phosphatase 2a and polynucleotides coding them |
| 04/15/2004 | WO2004031390A1 Vector system |
| 04/15/2004 | WO2004031357A2 Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors |
| 04/15/2004 | WO2004030702A1 Drug for auditory dysfunction |
| 04/15/2004 | WO2004030660A2 Compositions for treatment of prostate and other cancers |
| 04/15/2004 | WO2004030634A2 Therapeutic compositions |
| 04/15/2004 | WO2004030631A2 Anti-cancer and anti-infectious disease compositions and methods for using same |
| 04/15/2004 | WO2004030630A2 Focal calcium channel modulation |
| 04/15/2004 | WO2004030448A1 RELATIONSHIP BETWEEN LIPOPROTEIN (a) AND ATHEROMA SCLEROSIS |
| 04/15/2004 | WO2004011486A3 Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response |
| 04/15/2004 | WO2004009636A3 Gnrh modulator |
| 04/15/2004 | WO2004004451B1 Methods of screening compounds for grk6 modulating activity |
| 04/15/2004 | WO2004003209A3 Nucleic acid isolated from the 5' non translated region (5'ntr) end of the human fgf-1 gene having ires activity |
| 04/15/2004 | WO2004000875A3 Novel kcnq polypeptides, modulators thereof, and their uses in the treatment of mental disorders |
| 04/15/2004 | WO2003103704A3 L(2)44 dea, wunen-2, grapes, cg2221, cg1172, rutabaga, cg11940, facl involved in the regulation of energy homeostasis |